eligibility_summary
Eligible: metastatic/locally advanced non‑squamous NSCLC with EGFR del19/L858R (±T790M), no osimertinib‑resistance mutations, c‑MET overexpression by IHC, ECOG 0–1, measurable disease, prior 3rd‑gen EGFR TKI with progression, platinum‑eligible, treated/stable CNS mets allowed, prior RT fibrosis allowed. Exclude: adenosquamous/sarcomatoid or small‑cell, ALK/ROS1/BRAF drivers, prior metastatic chemo, ILD/pneumonitis, unresolved ≥G2 AEs, recent major surgery, liver disease, ≥G2 edema/ascites/effusion/neuropathy, active infection/corneal disorder.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 (withdrawn) randomized study in EGFR-mutant, c-MET–overexpressing metastatic non-squamous NSCLC after progression on a third-generation EGFR TKI. Interventions: telisotuzumab vedotin (ABBV-399), an IV anti-MET antibody-drug conjugate delivering the microtubule toxin MMAE, combined with oral osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor, versus platinum/pemetrexed chemotherapy (cisplatin or carboplatin: DNA crosslinking platinum agents, pemetrexed: antifolate inhibiting thymidylate synthase and purine synthesis). Targets/pathways: MET-overexpressing tumor cells, EGFR signaling, microtubules/mitosis, DNA replication/repair, and folate-dependent nucleotide synthesis.